We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Clinical Trials With a Live Attenuated Rubella Virus Vaccine:  Cendehill 51 Strain

R. Martin Du Pan, MD; C. Huygelen, DVM; J. Peetermans, BSc; A. Prinzie, MD
Am J Dis Child. 1968;115(6):658-662. doi:10.1001/archpedi.1968.02100010660004.
Text Size: A A A
Published online

IN VITRO and in vivo properties of the attenuated Cendehill strain of rubella virus have been described previously. This strain has been attenuated by serial propagation in primary rabbit kidney cells. It is characterized by the production of an early cytopathic effect in rabbit cultures, by the formation of distinct plaques in RK13 cells, by loss of intranasal infectivity for the monkey, and by loss of immunogenicity for the rabbit after subcutaneous inoculation.1,2 Preliminary clinical trials with the Cendehill strain at the 21st and 51st passage levels have been reported previously.3-6

Although attenuated virus at the 21st passage failed to spread from vaccinated subjects to susceptible contacts, the trials with this passage level were discontinued because mild but typical symptoms of rubella were observed in one of the vaccinees.4 We report here the results of several clinical trials in children and young adults, with the high-passage


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.